Search research articles
Contact Us
Filters
Showing results (361-370 of 386) with videos related to
Page
of 39
Sort By:
Journal of Cellular Physiology
|
July 23, 2011
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells
Belal Azab, Rupesh Dash, Swadesh K Das, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Anahita Dastur, AHyun Choi, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 11, 2011
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity
Rupesh Dash, Belal Azab, Bridget A Quinn, et al.
Anti-Cancer Drugs
|
July 9, 2010
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside
Paul Dent, Adly Yacoub, Hossein A Hamed, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Expert Opinion on Investigational Drugs
|
August 20, 2011
Targeting Mcl-1 for the therapy of cancer
Bridget A Quinn, Rupesh Dash, Belal Azab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Leukemia & Lymphoma
|
August 19, 2015
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, et al.
Cytokine & Growth Factor Reviews
|
October 8, 2010
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity
Rupesh Dash, Sujit K Bhutia, Belal Azab, et al.
Page
of 39
Search research articles
Search
Showing results (361-370 of 386) with videos related to
Sort By:
Page
of 39
Journal of Cellular Physiology
|
July 23, 2011
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells
Belal Azab, Rupesh Dash, Swadesh K Das, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Anahita Dastur, AHyun Choi, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 11, 2011
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity
Rupesh Dash, Belal Azab, Bridget A Quinn, et al.
Anti-Cancer Drugs
|
July 9, 2010
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside
Paul Dent, Adly Yacoub, Hossein A Hamed, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Expert Opinion on Investigational Drugs
|
August 20, 2011
Targeting Mcl-1 for the therapy of cancer
Bridget A Quinn, Rupesh Dash, Belal Azab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Leukemia & Lymphoma
|
August 19, 2015
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, et al.
Cytokine & Growth Factor Reviews
|
October 8, 2010
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity
Rupesh Dash, Sujit K Bhutia, Belal Azab, et al.
Page
of 39